JP2023513901A - タウオパチーの治療方法 - Google Patents

タウオパチーの治療方法 Download PDF

Info

Publication number
JP2023513901A
JP2023513901A JP2022548978A JP2022548978A JP2023513901A JP 2023513901 A JP2023513901 A JP 2023513901A JP 2022548978 A JP2022548978 A JP 2022548978A JP 2022548978 A JP2022548978 A JP 2022548978A JP 2023513901 A JP2023513901 A JP 2023513901A
Authority
JP
Japan
Prior art keywords
deuterated
optionally substituted
acid
ester
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513901A5 (enExample
Inventor
シチェピノフ、ミハイル、セルゲーエヴィチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Retrotope Inc
Original Assignee
Retrotope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrotope Inc filed Critical Retrotope Inc
Publication of JP2023513901A publication Critical patent/JP2023513901A/ja
Publication of JP2023513901A5 publication Critical patent/JP2023513901A5/ja
Priority to JP2025202414A priority Critical patent/JP2026035680A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022548978A 2020-02-14 2021-02-12 タウオパチーの治療方法 Pending JP2023513901A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025202414A JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976958P 2020-02-14 2020-02-14
US62/976,958 2020-02-14
PCT/US2021/017981 WO2021163580A1 (en) 2020-02-14 2021-02-12 Methods for treating tauopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025202414A Division JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Publications (2)

Publication Number Publication Date
JP2023513901A true JP2023513901A (ja) 2023-04-04
JP2023513901A5 JP2023513901A5 (enExample) 2024-02-20

Family

ID=77273602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548978A Pending JP2023513901A (ja) 2020-02-14 2021-02-12 タウオパチーの治療方法
JP2025202414A Pending JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025202414A Pending JP2026035680A (ja) 2020-02-14 2025-11-25 タウオパチーの治療方法

Country Status (9)

Country Link
US (2) US20210251933A1 (enExample)
EP (1) EP4103169A4 (enExample)
JP (2) JP2023513901A (enExample)
KR (1) KR20220140808A (enExample)
CN (1) CN116507325A (enExample)
AU (1) AU2021220981A1 (enExample)
CA (1) CA3171330A1 (enExample)
IL (1) IL295512A (enExample)
WO (1) WO2021163580A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240064584A (ko) * 2021-02-05 2024-05-13 레트로토프 인코포레이티드 중수소화 아라키돈산을 사용한 신경퇴행성 질환의 치료에 대한 환자의 반응을 평가하는 방법
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US20230165824A1 (en) * 2021-09-03 2023-06-01 Biojiva Llc METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs
CN118201607A (zh) * 2021-09-03 2024-06-14 拜奥吉瓦有限责任公司 利用氘代pufa抑制细胞功能障碍和细胞死亡的方法、系统和组合物
CA3243042A1 (en) * 2021-12-21 2025-04-08 Biojiva Llc METHODS AND COMPOSITIONS INTENDED FOR THE TREATMENT OF INFLAMMATORY DISEASE
WO2023192406A2 (en) * 2022-03-30 2023-10-05 Retrotope, Inc. Prophylactic methods for treating als

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509439A (ja) * 2009-10-30 2013-03-14 レトロトップ、 インコーポレイテッド Ｐｕｆａ誘導体による酸化ストレス障害の緩和
JP2014513098A (ja) * 2011-04-26 2014-05-29 レトロトップ、 インコーポレイテッド 神経変性障害および筋疾患に関与するｐｕｆａ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058522B2 (en) * 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
WO2018094116A1 (en) * 2016-11-17 2018-05-24 Retrotope, Inc. Isotopically modified components and therapeutic uses thereof
EP3461479B1 (en) * 2017-09-27 2021-06-16 Julie Blivet Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
EP3806841A1 (en) * 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Decreasing immune activity through modulation of postcellular signaling factors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509439A (ja) * 2009-10-30 2013-03-14 レトロトップ、 インコーポレイテッド Ｐｕｆａ誘導体による酸化ストレス障害の緩和
JP2014513098A (ja) * 2011-04-26 2014-05-29 レトロトップ、 インコーポレイテッド 神経変性障害および筋疾患に関与するｐｕｆａ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHMED ELHARRAM ET AL., THE FEBS JOURNAL, vol. 284, JPN6025004854, 2017, pages 4083 - 4095, ISSN: 0005795512 *
LUC BUEE AND ANDRE DELACOURTE, BRAIN PATHOLOGY, vol. 9, JPN6025004853, pages 681 - 693, ISSN: 0005795513 *
SOPHIA M.RAEFSKY ET AL., NEUROBIOL AGING, vol. 66, JPN6025004855, 2018, pages 165 - 176, ISSN: 0005795511 *

Also Published As

Publication number Publication date
US20210251933A1 (en) 2021-08-19
JP2026035680A (ja) 2026-03-04
US20250177339A1 (en) 2025-06-05
CN116507325A (zh) 2023-07-28
AU2021220981A1 (en) 2022-09-22
WO2021163580A1 (en) 2021-08-19
EP4103169A4 (en) 2024-03-13
IL295512A (en) 2022-10-01
KR20220140808A (ko) 2022-10-18
CA3171330A1 (en) 2021-08-19
EP4103169A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
JP2026035680A (ja) タウオパチーの治療方法
DK2442647T3 (en) Dithiolforbindelser, derivatives thereof, and the uses of these
US20250215026A1 (en) Deuterated Compounds, Compositions and Uses
ES2812800T3 (es) Nuevos usos terapéuticos de derivados de la bencilidenguanidina para el tratamiento de proteopatías
US20240041847A1 (en) Compounds and methods of treating retinal degeneration
US20040053989A1 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
JP5649585B2 (ja) ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物
RS57624B1 (sr) Nova sukcinatna jedinjenja koja prodiru u ćelije
TW202045150A (zh) PPARẟ促效劑於治療脂肪酸氧化異常(FAOD)之用途
WO2008060332A2 (en) Methods for treating or reducing muscle fatigue
Pagano et al. Mitigating the pro-oxidant state and melanogenesis of Retinitis pigmentosa: By counteracting mitochondrial dysfunction
ES2959243T3 (es) Nuevo tratamiento de enfermedades mitocondriales
WO2017168137A1 (en) Pyrimidobenzimidazoles for use in the treatment and prevention of neurodegenerative disorders
EP3187185A1 (en) Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound
JP2006516629A (ja) 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法
EP2522394B1 (en) Substituted phosphonates and their use decreasing amyloid aggregates
JP7598195B2 (ja) 肥満及び関連する障害の予防及び治療のための化合物
CA3056873A1 (en) Derivatives of sulindac can protect normal cells against oxidative damage
Tan et al. Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
HK40106579B (en) Administration and dosage of diaminophenothiazines
HK1229161A1 (en) Dithiol compounds, derivatives, and uses therefor
HK1229161A (en) Dithiol compounds, derivatives, and uses therefor
BR112016023086B1 (pt) Composto, composição, e, uso de um composto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251125

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260512